Accuracy of Revised Bethesda Guidelines, Microsatellite Instability, and Immunohistochemistry for the Identification of Patients With Hereditary Nonpolyposis Colorectal Cancer
- Virgínia Piñol, MD;
- Antoni Castells, MD;
- Montserrat Andreu, MD;
- Sergi Castellví-Bel, PhD;
- Cristina Alenda, MD;
- Xavier Llor, MD;
- Rosa M. Xicola, PhD;
- Francisco Rodríguez-Moranta, MD;
- Artemio Payá, MD;
- Rodrigo Jover, MD;
- Xavier Bessa, MD;
- for the Gastrointestinal Oncology Group of the Spanish Gastroenterological Association
- Author Affiliations: Department of Gastroenterology, Institut de Malalties Digestives, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona (Drs Piñol, Castells, Castellví-Bel, and Rodríguez-Moranta); Department of Gastroenterology, Hospital del Mar, Barcelona (Drs Andreu and Bessa); Departments of Pathology (Drs Alenda and Payá) and Gastroenterology (Dr Jover), Hospital General Universitario de Alicante, Alicante; and Department of Gastroenterology, Hospital Universitari Germans Trias i Pujol, Badalona (Drs Llor and Xicola), Spain.
- Corresponding Author: Antoni Castells, MD, Department of Gastroenterology, Hospital Clí@nic, Villarroel 170, 08036 Barcelona, Spain (castells{at}clinic.ub.es).
Abstract
Context The selection of individuals for hereditary nonpolyposis colorectal cancer (HNPCC) genetic testing is challenging. Recently, the National Cancer Institute outlined a new set of recommendations, the revised Bethesda guidelines, for the identification of individuals with HNPCC who should be tested for microsatellite instability.
Objective To establish the most effective and efficient strategy for the detection of MSH2/MLH1 gene carriers.
Design, Setting, and Patients A prospective, multicenter, nationwide study (the EPICOLON study) in 20 hospitals in the general community in Spain of 1222 patients with newly diagnosed colorectal cancer between November 1, 2000, and October 31, 2001.
Interventions Microsatellite instability testing and MSH2/MLH1 immunostaining in all patients regardless of age, personal or family history, and tumor characteristics. Patients whose tumors exhibited microsatellite instability and/or lack of protein expression underwent MSH2/MLH1 germline testing.
Main Outcome Measures Effectiveness and efficiency of both microsatellite instability testing and immunostaining, either directly or previous selection of patients according to the revised Bethesda guidelines, were evaluated with respect to the presence of MSH2/MLH1 germline mutations.
Results Two hundred eighty-seven patients (23.5%) fulfilled the revised Bethesda guidelines. Ninety-one patients (7.4%) had a mismatch repair deficiency, with tumors exhibiting either microsatellite instability (n = 83) or loss of protein expression (n = 81). Germline testing identified 11 mutations (0.9%) in either MSH2 (7 cases) or MLH1 (4 cases) genes. Strategies based on either microsatellite instability testing or immunostaining previous selection of patients according to the revised Bethesda guidelines were the most effective (sensitivity, 81.8% and 81.8%; specificity, 98.0% and 98.2%; positive predictive value, 27.3% and 29.0%, respectively) to identify MSH2/MLH1 gene carriers. Logistic regression analysis confirmed the revised Bethesda guidelines as the most discriminating set of clinical parameters (odds ratio, 33.3; 95% confidence interval, 4.3-250; P = .001).
Conclusion The revised Bethesda guidelines constitute a useful approach to identify patients at risk for HNPCC. In patients fulfilling these criteria, both microsatellite instability testing and immunostaining are equivalent and highly effective strategies to further select those patients who should be tested for MSH2/MLH1 germline mutations.
